Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Duffel – page 17

1 991 clinical trials in Duffel, Belgium across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Duffel at a glance
1 991
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 991 trials in Duffel

Open in trial search

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Duchenne Muscular Dystrophy in Patients with Gene Mutations Amenable to Exon 44 Skipping Treated with Delpacibart Zotadirsen

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Delpacibart zotadirsen
  • Sponsor:Avidity Biosciences Inc.

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Bisoprolol in Patients After Myocardial Infarction with Preserved Ejection Fraction During Cardiac Rehabilitation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol
  • Sponsor:UZ Leuven

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:EIK1005 sodium
  • Sponsor:Eikon Therapeutics Inc.

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Deciphera Pharmaceuticals Inc.

Endometriosis

Recruiting

Letrozole During IVF/ICSI for Women with Endometriosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Letrozole
  • Sponsor:UZ Brussel

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Dyslipidaemia

Recruiting

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid
  • Sponsor:A. Menarini International Licensing S.A.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Duffel

What the registry says about research in the country

01 Mental Health Research

Groundbreaking research focusing on Major Depressive Disorder and treatment-resistant depression, exploring novel therapeutic approaches and augmentation strategies.

  • Antidepressant Augmentation Studies
  • Treatment Response Assessment
  • Dose Optimization Research

Current trials are evaluating innovative treatment combinations and dosing strategies for patients who haven't achieved optimal results with standard therapies.

02 Psychiatric Disorders

Comprehensive research into schizophrenia, particularly focusing on cognitive impairment and long-term treatment outcomes with novel therapeutic agents.

  • Cognitive Function Studies
  • Long-term Safety Assessments
  • Treatment Effectiveness Monitoring

These studies aim to enhance our understanding of long-term treatment safety and efficacy in schizophrenia management.

03 Innovative Therapies

Exploring immune-targeted treatments and novel pharmaceutical approaches for treatment-resistant depression, including anti-inflammatory strategies.

  • Inflammation-based Treatments
  • Alternative Therapeutic Approaches
  • Biomarker Studies

Research focuses on identifying and validating new treatment pathways for patients who haven't responded to conventional therapies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.